Manufacturers submit new drug application for maralixibat to FDA for cholestatic pruritus in patients with Alagille syndrome

The submission for this selective inhibitor of the apical sodium-dependent bile acid transporter as a treatment for this rare genetic bile duct disorder is based on data from the Phase 2 ICONIC study. Maralixibat was previously granted Rare Paediatric Disease Designation in US.

Source:

Biospace Inc.